Where can I find the primary clinical evidence?

Primary trials are published in peer-reviewed journals (NEJM, JAMA, Lancet) with PubMed PMIDs cited throughout GLP1 One Rx.

SUSTAIN Trial Results — T2D Cardiovascular Safety

SUSTAIN Trial Results

Updated October 16, 2026 with prices and facts re-checked October 14, 2026.

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

Clinical referencePubMed-linkedUpdated October 16, 2026

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

PubMed citations

PMID 27633186

Related clinical pages

Questions readers ask

What was the SUSTAIN program?

SUSTAIN was the type 2 diabetes development program for semaglutide, and it led to Ozempic’s 2017 FDA approval. It focused on adults with type 2 diabetes rather than weight management.

What did SUSTAIN-6 show about heart safety?

SUSTAIN-6 (NEJM 2016, PMID 27633186) studied adults with type 2 diabetes and high cardiovascular risk, demonstrating cardiovascular safety with a 26% reduction in major adverse cardiovascular events.

How is SUSTAIN-6 different from SELECT?

SUSTAIN-6 enrolled adults with type 2 diabetes at high cardiovascular risk, while SELECT enrolled adults without diabetes who had overweight or obesity plus established cardiovascular disease, using semaglutide 2.4 mg.